[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autoantibodies-screening\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autoantibodies-screening":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100620979","analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav15-autoantibodies-in-patients-with-metastatic-tumors-100620979",false,"NCT07364656","Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic\n* Patients already receiving first-line therapy with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic\n* Signed informed consent\n\nExclusion Criteria:\n\n* Clinically significant cardiovascular diseases (atrial fibrillation, congestive heart failure, cardiomyopathies, or inherited arrhythmic syndromes)\n* Known autoimmune diseases or immunodeficiencies\n* Use of high-dose immunosuppressive drugs or other experimental treatments that could interfere with the assessment of study endpoints","ALL",{"count":17,"type":18},196,"ESTIMATED","INTERVENTIONAL",[21],"NA","The overall aim of this study is to identify and characterize anti-NaV1.5 autoantibodies in patients with metastatic breast and colorectal cancer. These tumors are characterized by the presence of a specific target structure (called nNaV1.5) against which antibodies are produced. These antibodies may cross-react with a similar structure (called NaV1.5) that is found in the heart. This could affect channel function and increase the risk of arrhythmias.",[24,25,26,27,28],"Brugada Syndrome (BrS)","Breast Cancer Females","Colon Cancer","ECG Abnormalities","Autoantibodies Screening","NOT_YET_RECRUITING","2026-01-16",{"date":32,"type":33},"2026-01-23","ACTUAL",{"date":35,"type":18},"2026-01",{"date":37,"type":18},"2026-12",{"name":39,"class":40},"IRCCS Policlinico S. Donato","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":15,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100567255","a-national-screening-program-for-islet-autoantibodies-among-first-degree-relatives-of-t1d-patients-100567255","NCT06665815","A National Screening Program for Islet Autoantibodies Among First-degree Relatives of T1D Patients","ADIR Families","Inclusion Criteria:\n\n* Age 2-45 years\n* First-degree relatives of Type 1 Diabetes probands\n* Signing an informed consent\n\nExclusion Criteria:\n\n* Known diabetes of any kind (type 1, type 2, MODY)\n* Have a previous history of being treated with insulin or oral diabetes medications.\n* Currently, using systemic immunosuppressive agents (topical and inhaled agents are acceptable)",true,"2 Years","45 Years",{"count":53,"type":18},20000,"OBSERVATIONAL","A national Screening program for the presence of Islet Autoantibodies (IA) in relatives of people with type 1 diabetes (PWT1D) aiming at identifying people with pre-clinical (stage 1 \\& 2) T1D and DKA prevention on the clinical presentation of T1D. All participants will be screened at study entry for the presence of 4 islet autoantibodies: glutamic acid decarboxylase antibody (GADA), insulinoma-associated-2 antibody (IA-2A), insulin antibodies (IAA) and Zinc transporter-8 antibodies (ZnT8A). The ADAP assay will be used to detect IA.\n\nA confirmation blood sample for positive participants with two or more IA will be taken. The confirmation analysis will be done by the ADAP assay, conventional ELISA, and RIA.\n\nParticipants identified as part of the study with pre-symptomatic type 1 diabetes (T1D) (stages 1 and 2) will be referred to complete an educational program emphasizing DKA prevention as part of routine medical care .During the study, cases of stage 2 and stage 3 diabetes and DKA events in participants who are positive for IA will be documented.",[57,28],"Type 1 Diabetes","RECRUITING","2025-05-15",{"date":61,"type":33},"2025-05-20",{"date":63,"type":33},"2024-12-15",{"date":65,"type":18},"2028-02-15",{"name":67,"class":40},"Rabin Medical Center"]